Study Comparing Cobolimab, Dostarlimab, and Docetaxel Combinations for Advanced Non-Small Cell Lung Cancer

Inclusion Criteria

• Have advanced or metastatic non-small cell lung cancer (NSCLC) confirmed by lab tests.
• Have received no more than two previous treatments for advanced cancer, including a platinum-based chemotherapy and an anti-PD-1 or anti-PD-(L)1 therapy.
• Have cancer that can be measured by scans.
• Have shown disease progression after previous treatments.
• Agree to provide a tumor sample from a previous biopsy or undergo a new biopsy if needed.
• Have a performance status score of 0 or 1, indicating full activity or some restriction in strenuous activities.
• Have a life expectancy of at least 3 months.
• Have adequate organ function based on medical tests.
• Have recovered from any side effects of previous treatments.
• Agree to use effective contraception during the study.

Exclusion Criteria

• Have previously stopped anti-PD-(L)1 or anti-PD-L2 treatment due to severe side effects.
• Have been treated with certain other immune therapies or docetaxel before.
• Have specific genetic mutations (EGFR, ALK, ROS-1) unless tested and confirmed negative.
• Experienced rapid disease progression within 8 weeks of starting previous anti-PD-1 or anti-PD-L1 therapy.
• Have received high-dose lung radiation within 6 months or palliative radiation within 7 days before starting the study.
• Have certain liver conditions or abnormal liver function tests.
• Have untreated or progressing brain metastases unless stable after treatment.
• Test positive for hepatitis B, hepatitis C, or HIV.
• Have active autoimmune diseases requiring treatment in the past 2 years.
• Have symptomatic fluid buildup in the abdomen or around the lungs unless stable after treatment.
• Have lung diseases like pneumonitis or interstitial lung disease.
• Have severe nerve damage.
• Have received a live vaccine within 30 days before starting the study.
• Cannot stop taking certain medications like aspirin before a biopsy if needed.